CAG方案治疗复发急性髓系白血病的疗效及安全性分析

The efficacy and safety analysis of aclacinomycin,cytarabine with granulocyte colony - stimulating factor in treatment of relapsed acute myeloid leukemia

目的探讨阿克拉霉素、阿糖胞苷联合粒细胞集落刺激因子治疗复发急性髓系白血病(AML)的临床疗效及安全性。方法将50例复发AML患者分为实验组和对照组各25例,实验组给予阿克拉霉素、阿糖胞苷联合粒细胞集落刺激因子(CAG方案)治疗,对照组给予阿克拉霉素、阿糖胞苷联合足叶乙苷(AEA方案),比较两组的临床疗效及安全性。结果实验组患者中10例获得完全缓解,12例部分缓解,总有效率为88%,与对照组比较差异有统计学意义(P<0.05);实验组治疗相关不良反应发生率为20.0%明显低于对照组的40.0%,两组比较差异有统计学意义(P<0.05)。结论 CAG方案治疗复发AML可有效地改善患者的临床症状,为疾病的进一步治疗赢了时间。

Objective To explore the clinical efficacy and safety of aclacinomycin, cytarabine combined with granulocyte colony - stimulating factor in the treatment of relapsed acute myeloid leukemia. Methods The clinical data of 50 patients with relapsed acute myeloid leukemia were retrospectively analyzed in our hospital, and all patients were divided into observation group and control group with 25 cases in each group. The observation group was given aclacinomycin, cytidine and granulocyte colony -stimulating factor （CAG program） therapy, while the control group was given aelacinomycin, cytarabine and etoposide （AEA program）, then the clinical efficacy and safety of the two groups were compared. Results Among the observation group, ten cases had complete remission, 12 cases had partial remission, and the total effective rate was 88% ; the difference was statistically significant compared with the control group （P 〈 0.05 ）. The adverse reactions of the observation group was 20.0%, which significantly lower than the 40.0% of control group, and the difference was statistically significant （ P 〈 0.05）. Conclusion CAG regimen in the treatment of relapsed acute myeloid leukemia can be effective in improving the clinical symptoms, win the effective time for further diagnosis and treatment of the disease.